Home ••• Newswires by Industry • Countries • U.S. States • World Media Directory

Pharmaceutical Industry News ••• Topics • Countries • U.S. States

Paclitaxel News Monitoring

Get by Email • RSS

Published on 02:36 GMT

[ASCO 2025] Enhertu shows prolonged survival in 2nd-line treatment of gastric cancer

CHICAGO, Ill.--By Kim Yun-mi/Korea Biomedical Review correspondent--Enhertu (trastuzumab deruxtecan) has demonstrated remarkable results in patients with HER2-positive advanced gastric cancer. Results from the phase 3 DESTINY-Gastric04 study, presented …

Source: Korea Biomedical Review - Neutral
Published on Jun 1, 2025

Addition of TTFields to Gemcitabine/Nab-Paclitaxel Boosts OS in Locally Advanced PDAC

Treatment with tumor-treating fields (TTFields) in combination with gemcitabine and nab-paclitaxel (Abraxane) led to a statistically significant improvement in superior overall survival (OS) compared with gemcitabine plus nab-paclitaxel alone in patients …

Source: OncLive - Pending
Published on Jun 1, 2025

First-Line Fruquintinib Combo May Offer New Treatment Strategy in ESCC

Frontline treatment with fruquintinib (Fruzaqla) plus camrelizumab, paclitaxel liposome, and nedaplatin elicited responses with an acceptable safety profile in patients with advanced esophageal squamous cell carcinoma (ESCC), according to findings from a …

Source: OncLive - Pending
Published on Jun 1, 2025

Dr Picozzi on the Addition of TTFields to Gemcitabine and Nab-Paclitaxel in Locally Advanced PDAC

"The use of TTFields did produce a statistically significant improvement in overall survival over [chemotherapy alone]. This is important in that this is first positive trial ever in this stage of pancreatic cancer, and it also provides a foundation …

Source: OncLive - Pending
Published on May 31, 2025

Enhertu Improves Survival End Points Vs Cyramza/Paclitaxel in HER2+ GC/GEJ

Among patients with HER2-positive unresectable or metastatic gastric cancer or gastroesophageal junction adenocarcinoma (GC/GEJ), second-line treatment with Enhertu (fam-trastuzumab deruxtecan-nxki) had a clinically meaningful and statistically …

Source: Cure Today - Neutral
Published on Jun 1, 2025

Addition of Elraglusib Improves Survival in Metastatic Pancreatic Cancer

A trial of elraglusib plus gemcitabine/nab-paclitaxel met its primary end point of superior overall survival (OS) vs gemcitabine/nab-paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC), according to findings presented at …

Source: Targeted Oncology - Pending
Published on May 31, 2025

Meitheal Pharma launches generic paclitaxel formulation in US via exclusive commercial licensing agreement with Hong ...

Meitheal Pharmaceuticals, Inc (Meitheal), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, announced it has launched, …

Source: Pharmabiz.com - Neutral
Published on May 31, 2025

OncLive’s FDA Approval Report: The Regulatory Rundown for May 2025

Below is your guide to all the oncologic therapeutic options cleared by the FDA in May 2025. The roundup provides everything you need to know, right at your fingertips—all the topline data that supported the decisions and expert insights contextualizing …

Source: OncLive - Pending
Published on May 30, 2025

BioLineRx Soars on Pancreatic Cancer Trial Buzz: What’s Driving the Surge?

The Big News Shaking Up BLRX BioLineRx (NASDAQ: BLRX), a scrappy biopharmaceutical player out of Israel, is stealing the spotlight today, and for good reason. The company just dropped a bombshell announcement: new data from the pilot phase of its …

Source: Raging Bull - New Hampshire - Neutral
Published on Jun 1, 2025

Neoadjuvant PAXG Outperforms mFOLFIRINOX in Resectable and Borderline Resectable PDAC

Final results of the phase 3 CASSANDRA trial (NCT04793932) demonstrated that PAXG (cisplatin, nab-paclitaxel, gemcitabine, and capecitabine) is superior to modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant chemotherapy for the treatment of patients with …

Source: Targeted Oncology - Pending
Published on May 30, 2025

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company announced …

Source: myMotherLode - Pending
Published on May 30, 2025

BioLineRx Announces New Pilot Phase Data from Phase 2 Combination Trial of Motixafortide in First-Line Pancreatic Cancer ...

- 4 of 11 PDAC patients in the pilot phase remained progression free at over one year - Poster presentation on Saturday, May 31st TEL AVIV, Israel, May 30, 2025 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ/TASE: BLRX), a development stage …

Source: WFMZ - Pennsylvania - Neutral
Published on May 29, 2025

Intraprostatic drug elution therapy shows promise for BPH-related LUTS

Paclitaxel eluting bioabsorbable implants demonstrated encouraging efficacy and appeared to be safe and feasible in the management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), according to 6-month data from a …

Source: Urology Times - Pending
Published on May 29, 2025

Mechanisms of Zanthoxyli Pericarpium-Zingiberis Rhizoma in the Treatment of Gastric Cancer Based on Network Pharmacology ...

Introduction Gastric cancer is a malignant tumor originating from the epithelium of the gastric mucosa. Currently, gastric cancer stands as the fifth most common malignancy in incidence and the fourth in mortality, exerting a substantial impact on patients …

Source: Dove Medical Press - Neutral
Published on May 31, 2025

T-DXd Emerges as New Standard of Care for Second-Line HER2+ Gastric/GEJ Cancer

Fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) demonstrated a clinically meaningful and statistically significant improvement in overall survival (OS) vs ramucirumab (Cyramza) plus paclitaxel in the second-line treatment of patients with HER2-positive …

Source: Cancer Network - New Jersey - Pending
Published on May 31, 2025

Sacituzumab Govitecan/Pembrolizumab Show Promise as SOC in 1st Line PD-L1+ TNBC

Sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda) in the first line significantly improved PFS vs chemotherapy plus pembrolizumab for patients with PD-L1–positive, advanced or metastatic triple-negative breast cancer (TNBC), based on …

Source: Cancer Network - New Jersey - Pending
Published on May 31, 2025

Satri-cel Makes Strides in Gastric and Gastroesophageal Junction Cancer

New results from the phase 2 pivotal trial of satricabtagene autoleucel (satri-cel), a Claudin18.2 (CLDN18.2)-targeting autologous CAR T-cell therapy in development by CARsgen, presented at the 2025 American Society of Clinical Oncology (ASCO) Annual …

Source: CGTLive - Neutral
Published on May 31, 2025

Second-line trastuzumab deruxtecan improves survival for advanced gastric cancers

Add topic to email alerts Subscribe We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Back to Healio Key takeaways: Second-line trastuzumab deruxtecan-nxki …

Source: Healio News - Neutral
Published on May 31, 2025

Late-breaking analysis demonstrates characteristics associated with long-term overall survival with Onivyde® regimen in ...

Phase III NAPOLI 3 trial is the largest and has the longest follow-up for an interventional study in metastatic pancreatic adenocarcinoma1 Post-hoc analysis of NAPOLI 3 study determined characteristics associated with long-term survival, with median …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

29 days 22:45:00

Featured Releases

Got News to Share? · Submit · See All

Published on June 2, 2025 - 10:30 GMT

Hyperscale Data Reports $219 Million in Assets at End of Q1 2025, Sells Minority Stake in Private Pharmaceutical Company ...

LAS VEGAS, June 02, 2025 (GLOBE NEWSWIRE) -- Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced the sale of its minority equity interest in a privately held pharmaceutical …

Distribution channels:
Published on June 2, 2025 - 05:00 GMT

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short ...

Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) ( …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Published on June 2, 2025 - 05:00 GMT

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 05:00 GMT

Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques ...

Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce Le portefeuille de Sanofi s’enrichit du seul médicament approuvé, en croissance rapide, pour la …

Distribution channels:

Published on June 1, 2025 - 23:30 GMT

Nxera Pharma Achieves Development Milestone in Collaboration with Eli Lilly Targeting Metabolic Diseases

Tokyo, Japan and Cambridge, UK, 2 June 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) today announces that it has achieved a development milestone under its multi-target collaboration and license agreement with Eli Lilly and Company (“ …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 08:00 GMT

Aravax Appoints Louise Peacock as Chief Regulatory and Quality Officer as it Prepares for Phase 3 Development

MELBOURNE, Australia and OXFORD, United Kingdom, June 02, 2025 (GLOBE NEWSWIRE) -- Aravax, a clinical-stage biotechnology company developing next-generation, disease-modifying immunotherapies for food allergy, today announces the appointment of Louise …

Distribution channels: Companies, Technology ...
Published on June 2, 2025 - 10:45 GMT

BioNTech und Bristol Myers Squibb geben globale strategische Partnerschaft zur gemeinsamen Entwicklung und ...

BioNTechs bispezifischer PD-L1xVEGF-Antikörper BNT327 ist ein Immuntherapiekandidat in der fortgeschrittenen klinischen Entwicklung, der das Potenzial hat für verschiedene Tumorarten einen neuen Behandlungsstandard zu setzen, der über die traditionellen …

Distribution channels: Companies, Media, Advertising & PR ...
Published on June 2, 2025 - 09:30 GMT

Dr. Ushma Kakkad Earns Certification in Conscious Sedation with Nitrous Oxide from IDA

Certification empowers Dr. Kakkad to offer anxiety-free dental care using nitrous oxide for kids and adults at Summirow Dental Hospital. SURAT, GUJARAT, INDIA, June 2, 2025 /⁨EINPresswire.com⁩/ -- Introduction We’re proud to share some exciting …

Distribution channels: Healthcare & Pharmaceuticals Industry ...

Got news to share? Submit it now.

Load more pharmaceuticals news or search news using your own keywords. There are 818,228,902 articles in our news database.

Online News Monitoring Made Simple

Established in 1995, EIN Newsdesk helps millions of users track breaking news across thousands of trusted websites. Users may set up custom email newsletters and RSS feeds or search among thousands of preset news sections. As a member, you may also submit your own news using the EIN Presswire distribution service. Membership is free and we do not sell or lease any information about you. Press release distribution, dedicated APIs, and custom services generate the revenue that allow us to offer you free basic access.

News by Country & by Industry

Worldwide News Coverage

Track news across more than 5,000 sources by country or industry or search our real-time news index.

Pharmaceutical Industry News by Country

Pharmaceutical Industry News by U.S. State

Pharmaceutical Industry News Topics

Online News Publications

World News Report

News Alerts & News Feeds

Custom News Monitoring

News page results can be outputted as RSS or received daily by email. You may also use our NewsPlugin for WordPress.

Create Email Newsletter

Create RSS Feed

NewsPlugin for WordPress

Submit News

PR Distribution Service

Our EIN Presswire's distribution footprint reaches millions. You can upload news which is re-published through EIN Newsdesk, fed into Twitter and Facebook, and onto partner sites, Google News, Bing News, etc.

EIN Presswire

Events

World Media Directory

News Media Guide

This is a listing of the world’s TV stations, radio stations, newspapers, and blogs. Last update: 05/18/2025

World Media Directory

Healthcare & Pharmaceuticals Industry Press Releases

Got News to Share? · Submit · See All

Published on June 2, 2025 - 11:00 GMT

Functional Pathways Selected as Contract Therapy Partner for Covenant Living Communities

Covenant Living has selected Functional Pathways to serve as its exclusive contract therapy partner for its 20 communities across 11 states. KNOXVILLE, TN, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Functional Pathways, one of the nation’ …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 09:30 GMT

Dr. Ushma Kakkad Earns Certification in Conscious Sedation with Nitrous Oxide from IDA

Certification empowers Dr. Kakkad to offer anxiety-free dental care using nitrous oxide for kids and adults at Summirow Dental Hospital. SURAT, GUJARAT, INDIA, June 2, 2025 /⁨EINPresswire.com⁩/ -- Introduction We’re proud to share some exciting …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 08:08 GMT

Bracane Company Earns Ecovadis Silver Medal for Sustainability Excellence

Ranked Among Top 15% of Companies Globally, Underscoring Bracane’s Commitment to Environmental Stewardship, Social Responsibility, and Ethical Governance PLANO, TX, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Bracane Company, Inc., a …

Distribution channels: Education, Energy Industry ...
Published on June 2, 2025 - 07:49 GMT

MOIN Launches Cross-Border Remittance Service via Toss App, Enhancing Accessibility for 28 Million Users

MOIN, a leading fintech company specializing in cross-border remittance solutions, has launched its cross-border money transfer service on Toss SEOUL, EUNPYEONG, SOUTH KOREA, June 2, 2025 /⁨EINPresswire.com⁩/ -- MOIN, a leading fintech company …

Distribution channels: Amusement, Gaming & Casino, Automotive Industry ...
Published on June 2, 2025 - 06:51 GMT

Narconon Arrowhead Hosts Celebration for Graduate's 25 Years of Sobriety

CANADIAN, OK, UNITED STATES, June 1, 2025 /⁨EINPresswire.com⁩/ -- The Narconon Arrowhead Drug and Alcohol Rehabilitation Program recently hosted a special celebration as Bobby Newman, a program graduate, marked 25 years of sobriety. Newman, who …

Distribution channels: Culture, Society & Lifestyle, Education ...
Published on June 1, 2025 - 23:16 GMT

Luis M. Gallardo Launches the Meta Pets Method, A Playful Path to Transformation for Therapists, Coaches, and Educators

A Card-Based System for Self-Inquiry, Healing, and Awakening in Education, Coaching, and Therapy. MIAMI, FL, UNITED STATES, June 1, 2025 /⁨EINPresswire.com⁩/ -- Author, hypnotherapist, and global well-being advocate Luis Miguel Gallardo announces …

Distribution channels: Book Publishing Industry, Business & Economy ...
Published on June 2, 2025 - 11:00 GMT

BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology

RESEARCH TRIANGLE PARK, N.C., June 02, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that new data on oral, once-daily ORLADEYO® (berotralstat) for the prophylactic treatment of hereditary angioedema (HAE) will be …

Distribution channels: Culture, Society & Lifestyle, Healthcare & Pharmaceuticals Industry ...
Published on June 1, 2025 - 23:00 GMT

Impelsys Strengthens AI Transformation Strategy with AlgoShack Partnership

NEW YORK, NY, UNITED STATES, June 2, 2025 /⁨EINPresswire.com⁩/ -- Impelsys, a global leader in technology solutions, is pleased to announce its strategic partnership with AlgoShack, a company that offers algoQA—a unified platform for end-to-end …

Distribution channels: Book Publishing Industry, Education ...
Published on June 2, 2025 - 11:00 GMT

ASU, Labcorp, and InStride announce first-of-its-kind diagnostics industry partnership that tackles critical healthcare ...

LOS ANGELES, June 02, 2025 (GLOBE NEWSWIRE) -- InStride, a leading provider of strategic education and skilling solutions, has facilitated a unique partnership between Arizona State University’s College of Health Solutions and Labcorp, a global leader of …

Distribution channels: Companies, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 11:00 GMT

Outlook Therapeutics® Announces Commercial Launch of LYTENAVA™ (bevacizumab gamma) in Germany and the UK for the ...

LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 2.8 million injections of repackaged off-label bevacizumab in Europe each year1 ISELIN, N.J., …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 11:00 GMT

Recludix Pharma Announces Development Candidate Nomination of First-in-Class Oral STAT6 Inhibitor for Inflammatory ...

--Completion of GLP toxicology studies associated with a $50 million payment to Recludix under the collaboration with Sanofi -- REX-8756 is a potent and selective oral STAT6 inhibitor that demonstrates complete pathway inhibition and is well tolerated in …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 11:00 GMT

Lyra Therapeutics Reports Positive Results from the ENLIGHTEN 2 Phase 3 Trial of LYR-210 Achieving Statistically ...

ENLIGHTEN 2 trial met primary endpoint with LYR-210 demonstrating statistically significant improvement in the composite of the three cardinal symptoms (3CS) of CRS at 24 weeks (p=0.0078) ENLIGHTEN 2 trial also showed statistically significant improvement …

Distribution channels: Healthcare & Pharmaceuticals Industry, Science ...
Published on June 2, 2025 - 10:59 GMT

Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis

- Bosakitug is a Potential Best-in-Class Investigational Monoclonal Antibody with Demonstrated Superior Potency, Residence Time, and Affinity to Thymic Stromal Lymphopoietin (TSLP) - - Top Line Results Expected in the Second Half of 2026 - WAYNE, Pa., June …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 10:30 GMT

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA ...

Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared to placebo at week 36 (p<0.0001) Other prespecified …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 10:11 GMT

Xilio Therapeutics Announces Proposed Public Offering

WALTHAM, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it is …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 10:00 GMT

atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Strategic combination establishes a market-leading mental health company with a pipeline that includes potentially transformative, rapid-acting psychedelic assets differentiated by their convenient route of administration and short time-in-clinic Combined …

Distribution channels: Banking, Finance & Investment Industry, Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 05:00 GMT

Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short ...

Press release – No. 10 / 2025 Zealand Pharma submits Marketing Authorization Application to the European Medicines Agency for glepaglutide in short bowel syndrome Copenhagen, Denmark, June 2, 2025 – Zealand Pharma A/S (Nasdaq: ZEAL) (“Zealand”) ( …

Distribution channels: Healthcare & Pharmaceuticals Industry ...
Published on June 2, 2025 - 05:00 GMT

Press Release: Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-...

Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the Sanofi portfolio …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 05:00 GMT

Sandoz launches first and only interchangeable denosumab biosimilars in US, providing new affordable treatment options ...

Ad-hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules MEDIA RELEASE WYOST® (denosumab-bbdz) and Jubbonti® (denosumab-bbdz) are first and only FDA-approved interchangeable denosumab biosimilars available in US Improves access for patients …

Distribution channels: Healthcare & Pharmaceuticals Industry, Media, Advertising & PR ...
Published on June 2, 2025 - 05:00 GMT

Communiqué de presse : Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques ...

Sanofi acquiert Blueprint Medicines, enrichit son portefeuille dans les maladies immunologiques rares et ajoute un pipeline d’immunologie de stade précoce Le portefeuille de Sanofi s’enrichit du seul médicament approuvé, en croissance rapide, pour la …

Distribution channels: